A Phase 3 interventional study of AR-13324 Ophthalmic Solution 0.02% and Timolol maleate Ophthalmic Solution 0.5% BID in Ocular Hypertension and Open-angle Glaucoma, sponsored by Aerie Pharmaceuticals. Completed at 1 site in United States. Open to participants aged Up to 99 Years. Per ClinicalTrials.gov, last updated 2018-04-06.
Sponsored by Aerie Pharmaceuticals (part of Alcon) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing netarsudil in Glaucoma, Open-Angle — 3 open to participants now, 4 under way, none of them phase 3. netarsudil · Glaucoma, Open-Angle.
Among the 17 studies testing netarsudil in Glaucoma, Open-Angle, this one has the largest enrollment, is one of 2 that started in 2014, is one of 5 in phase 3, and was the 3rd registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →3 of the 17 studies testing netarsudil in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:
Brett King · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Center for Sight Las Vegas · Sites in United States
Ages 40+
By country, each count listing its studies:
netarsudil: first FDA approval 2017 (RHOPRESSA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: Up to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2014.
This study's enrollment of 756 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 85 across the 17 interventional studies. Of the 12 that completed or were terminated, 11 (92%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 17 have an industry lead sponsor. The 7 most frequent:
This study is registered under Aerie Pharmaceuticals, one of the names counted as Alcon. Under that name alone:
Aerie Pharmaceuticals is the lead sponsor of 36 studies on the registry; none are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
126 studies in Glaucoma, Open-Angle by Alcon: 1 open now, 1 under way, none of them phase 3. Of 121 finished, 58 (48%) have results posted.
Among the 126 studies in Glaucoma, Open-Angle by Alcon, this one is the 7th largest by enrollment of the 112 interventional ones that give a count, is one of 3 that started in 2014, is one of 43 in phase 3, and was the 103rd registered.
Alcon’s Glaucoma, Open-Angle studies by the year they started, since 1999.
2 of the studies testing netarsudil in Glaucoma, Open-Angle that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07048886Center for Sight Las VegasRocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery) | 2026-12-31 |
| NCT07325240Mayo Clinic24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies testing netarsudil in Glaucoma, Open-Angle, from their registry updates:
Among Alcon’s 126 in Glaucoma, Open-Angle:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Evaluation of the ocular hypotensive efficacy and safety of Netarsudil (AR-13324) Ophthalmic Solution compared to Timolol Maleate Ophthalmic Solution
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
This study's enrollment of 756 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Browse Glaucoma, Open-Angle studies →Aerie Pharmaceuticals is the lead sponsor of 36 studies on the registry; none are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
First submitted before Aerie Pharmaceuticals became part of Alcon.
Compared within Glaucoma, Open-Angle, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Ocular Hypertension. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Subject inclusion criteria
Subject exclusion criteria
Ophthalmic:
Any abnormality in either eye preventing reliable applanation tonometry of either eye.
Systemic:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 drop AR-13324 in the evening (PM) \& 1 drop placebo in the morning (AM) in both eyes (OU)
Drug: AR-13324 Ophthalmic Solution 0.02% · Other: Placebo
1 drop twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU)
Drug: Timolol maleate Ophthalmic Solution 0.5% BID
1 drop AR-13324 twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU)
Drug: AR-13324 Ophthalmic Solution 0.02% BID
1 drop once daily (QD), PM, OU
Also known as: Netarsudil
1 drop BID, AM/PM, OU
1 drop QD, AM, OU
1 drop BID, AM/PM, OU
Also known as: Netarsudil
Intraocular Pressure (IOP)
The primary efficacy outcome is mean intraocular pressure (IOP)
Time frame: 3 months
Extent of Exposure
Exposure to study medication in days for all treatment groups
Time frame: 12 Months
62 clinical trial sites participated in this study, of which 60 clinical trial sites enrolled participants. Screening started in June 2014. Enrollment started in July 2014. The last participant was enrolled in March 2015.
| Milestone | AR-13324 Ophthalmic Solution 0.02% & Placebo | Timolol Maleate Ophthalmic Solution 0.5% BID | AR-13324 Ophthalmic Solution 0.02% BID |
|---|---|---|---|
| Started | 251 | 251 | 254 |
| Completed | 146 | 204 | 86 |
| Not completed | 105 | 47 | 168 |
| Withdrew: Adverse event | 71 | 15 | 132 |
| Withdrew: Withdrawal by subject | 9 | 9 | 13 |
| Withdrew: Non-compliant | 3 | 3 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 3 |
| Withdrew: Lack of efficacy | 10 | 2 | 4 |
| Withdrew: Disallowed concurrent medication | 2 | 5 | 2 |
| Withdrew: Physician decision | 1 | 2 | 2 |
| Withdrew: Protocol violation | 4 | 10 | 6 |
| Withdrew: Death | 2 | 0 | 0 |
| Withdrew: Other(site,sponsor and subject request) | 2 | 1 | 5 |
The primary efficacy outcome is mean intraocular pressure (IOP)
| mmHg | AR-13324 Ophthalmic Solution 0.02% & Placebo | Timolol Maleate Ophthalmic Solution 0.5% BID | AR-13324 Ophthalmic Solution 0.02% BID |
|---|---|---|---|
| Day 1, 0800 hours | 23.51 ± 1.654 | 23.45 ± 1.601 | 23.50 ± 1.671 |
| Day 1, 1000 hours | 22.31 ± 2.131 | 22.18 ± 2.089 | 22.26 ± 2.103 |
| Day 1, 1600 hours | 21.56 ± 2.338 | 21.61 ± 2.369 | 21.49 ± 2.279 |
| Day 15, 0800 hours | 19.01 ± 2.979 | 18.25 ± 2.736 | 18.20 ± 3.491 |
| Day 15, 1000 hours | 17.74 ± 3.089 | 17.49 ± 2.796 | 16.91 ± 3.087 |
| Day 15, 1600 hours | 17.37 ± 2.830 | 17.59 ± 2.935 | 16.28 ± 2.925 |
| Day 43, 0800 hours | 19.37 ± 3.749 | 18.08 ± 2.614 | 18.57 ± 3.206 |
| Day 43, 1000 hours | 18.10 ± 3.335 | 17.31 ± 2.805 | 17.09 ± 3.028 |
| Day 43, 1600 hours | 17.88 ± 2.888 | 17.25 ± 2.813 | 16.58 ± 3.095 |
| Day 90 (Month 3), 0800 hours | 19.43 ± 3.761 | 18.21 ± 2.819 | 18.66 ± 3.460 |
| Day 90 (Month 3), 1000 hours | 18.18 ± 3.571 | 17.52 ± 2.777 | 17.81 ± 3.330 |
| Day 90 (Month 3), 1600 hours | 17.73 ± 3.386 | 17.67 ± 2.879 | 17.08 ± 3.112 |
Exposure to study medication in days for all treatment groups
| days | AR-13324 Ophthalmic Solution 0.02% & Placebo | Timolol Maleate Ophthalmic Solution 0.5% BID | AR-13324 Ophthalmic Solution 0.02% BID |
|---|---|---|---|
| Extent of Exposure | 259.7 ± 133.34 | 324.5 ± 90.73 | 185.2 ± 144.56 |
Collected over 1 year. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AR-13324 Ophthalmic Solution 0.02% & Placebo | 2/251 (0.8%) | 17/251 (6.8%) | 198/251 (78.9%) |
| Timolol Maleate Ophthalmic Solution 0.5% BID | 0/251 (0%) | 12/251 (4.8%) | 96/251 (38.2%) |
| AR-13324 Ophthalmic Solution 0.02% BID | 0/253 (0%) | 7/253 (2.8%) | 213/253 (84.2%) |
| Event | AR-13324 Ophthalmic Solution 0.02% & Placebo | Timolol Maleate Ophthalmic Solution 0.5% BID | AR-13324 Ophthalmic Solution 0.02% BID |
|---|---|---|---|
| Coronary Artery DiseaseCardiac disorders | 2/251 | 0/251 | 1/253 |
| Myocardial InfarctionCardiac disorders | 2/251 | 1/251 | 1/253 |
| Atrial FibrillationCardiac disorders | 2/251 | 0/251 | 0/253 |
| Atrial FlutterCardiac disorders | 1/251 | 0/251 | 0/253 |
| BradycardiaCardiac disorders | 1/251 | 0/251 | 0/253 |
| Breast CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/251 | 0/251 | 0/253 |
| Malignant Melanoma in SituNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/251 | 0/251 | 0/253 |
| Myelodysplastic SyndromeNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/251 | 0/251 | 0/253 |
| Prostate CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/251 | 0/251 | 0/253 |
| Postoperative IleusInjury, poisoning and procedural complications | 1/251 | 0/251 | 0/253 |
| Event | AR-13324 Ophthalmic Solution 0.02% & Placebo | Timolol Maleate Ophthalmic Solution 0.5% BID | AR-13324 Ophthalmic Solution 0.02% BID |
|---|---|---|---|
| Conjunctival HyperaemiaEye disorders | 152/251 | 35/251 | 168/253 |
| Cornea VerticillataEye disorders | 64/251 | 2/251 | 64/253 |
| Conjunctival HaemorrhageEye disorders | 49/251 | 2/251 | 49/253 |
| Instillation Site PainGeneral disorders | 45/251 | 41/251 | 45/253 |
| Vision BlurredEye disorders | 27/251 | 7/251 | 44/253 |
| Instillation Site ErythemaGeneral disorders | 14/251 | 5/251 | 32/253 |
| Lacrimation IncreasedEye disorders | 19/251 | 0/251 | 25/253 |
| Visual Acuity ReducedEye disorders | 22/251 | 6/251 | 22/253 |
| Eye PruritusEye disorders | 14/251 | 3/251 | 20/253 |
| Conjunctival OedemaEye disorders | 8/251 | 0/251 | 19/253 |
The randomized population includes all subjects who were randomized to treatment. Baseline variables and demographic characteristics were summarized for this population.
| Age, Continuous(Years) | AR-13324 Ophthalmic Solution 0.02% & Placebo | Timolol Maleate Ophthalmic Solution 0.5% BID | AR-13324 Ophthalmic Solution 0.02% BID | Total |
|---|---|---|---|---|
| Mean | 65.3 ± 11.48 | 63 ± 11.81 | 64.1 ± 12.46 | 64.1 ± 11.95 |
| Sex: Female, Male(Participants) | AR-13324 Ophthalmic Solution 0.02% & Placebo | Timolol Maleate Ophthalmic Solution 0.5% BID | AR-13324 Ophthalmic Solution 0.02% BID | Total |
|---|---|---|---|---|
| Female | 148 | 150 | 165 | 463 |
| Male | 103 | 101 | 89 | 293 |
| Ethnicity (NIH/OMB)(Participants) | AR-13324 Ophthalmic Solution 0.02% & Placebo | Timolol Maleate Ophthalmic Solution 0.5% BID | AR-13324 Ophthalmic Solution 0.02% BID | Total |
|---|---|---|---|---|
| Hispanic or Latino | 41 | 42 | 43 | 126 |
| Not Hispanic or Latino | 210 | 209 | 211 | 630 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | AR-13324 Ophthalmic Solution 0.02% & Placebo | Timolol Maleate Ophthalmic Solution 0.5% BID | AR-13324 Ophthalmic Solution 0.02% BID | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 0 | 0 | 2 |
| Asian | 2 | 6 | 6 | 14 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 69 | 76 | 69 | 214 |
| White | 178 | 166 | 177 | 521 |
| More than one race | 0 | 2 | 1 | 3 |
| Unknown or Not Reported | 0 | 1 | 1 | 2 |
Ran from Jul 2014 to primary completion in Mar 2016, 20 months.
Results were first posted in Apr 2018, 2 years 1 month after primary completion. A results delay was requested in Jul 2016.
Of 47 industry-sponsored phase 3 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's 20 months is below that.
Counting every sponsor, half of 49 studies reached it within 26 months; a quarter within 12 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Netarsudil